Serum samples from 298 patients with SS (including diffuse and limited disease) were evaluated for the presence of autoantibodies to angiotensin II type 1 receptor and endothelin-1 type A receptor.

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...